|Bid||317.25 x 200|
|Ask||320.00 x 100|
|Day's Range||316.55 - 319.41|
|52 Week Range||244.28 - 330.00|
|PE Ratio (TTM)||20.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biogen Inc (NASDAQ:BIIB) stock had a fantastic start to September with a 15% rally. Clearly, this is a momentum stock, so it will never give us a clear signal for entry. More often than not, traders tend to overshoot with the price action of momentum stocks.
With the market grinding higher, some breakouts struggle. But Apple, Microsoft, Biogen, Alexion Pharmaceuticals, Wynn Resorts and Electronic Arts are holding in buy zones after breaking out several days or weeks ago.
Last month, Gilead Sciences (GILD) made big news when it announced the acquisition of Kite Pharma (KITE). For the most part, analysts were bullish on the deal, with the noted exception being Leerink's Geoffrey Porges and Bradley Canino. The pair penned a note late last month explaining why they were not excited by Gilead’s latest purchase.